Suma Krishnan - Dec 29, 2022 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Signature
/s/ Suma Krishnan
Stock symbol
KRYS
Transactions as of
Dec 29, 2022
Transactions value $
-$1,560,411
Form type
4
Date filed
1/3/2023, 05:44 PM
Previous filing
Dec 20, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Sale -$601K -7.48K -0.44% $80.30 1.71M Dec 29, 2022 Direct F1, F2
transaction KRYS Common Stock Sale -$42.8K -528 -0.03% $81.10 1.71M Dec 29, 2022 Direct F1, F3
transaction KRYS Common Stock Sale -$598K -7.45K -0.42% $80.28 1.77M Dec 29, 2022 By Spouse F4, F5, F6, F7
transaction KRYS Common Stock Sale -$45.7K -563 -0.03% $81.11 1.77M Dec 29, 2022 By Spouse F4, F5, F7, F8
transaction KRYS Common Stock Sale -$137K -1.7K -0.1% $80.33 1.71M Jan 3, 2023 Direct F1, F9
transaction KRYS Common Stock Sale -$137K -1.7K -0.1% $80.33 1.77M Jan 3, 2023 By Spouse F4, F5, F7, F10
holding KRYS Common Stock 90K Dec 29, 2022 By SMK Trust
holding KRYS Common Stock 50K Dec 29, 2022 By Krishan Family Trust F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share.
F2 The transaction was executed in multiple trades ranging from $80.0000 to $80.9100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The transaction was executed in multiple trades ranging from $81.0000 to $81.2000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share.
F5 These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan.
F6 The transaction was executed in multiple trades ranging from $80.0000 to $80.9900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7 Directly beneficially owned by Krish S. Krishnan, the spouse of the reporting person.
F8 The transaction was executed in multiple trades ranging from $81.0000 to $81.2700. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9 The transaction was executed in multiple trades ranging from $80.0000 to $80.6700. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10 The transaction was executed in multiple trades ranging from $80.0000 to $80.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F11 Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.